Get the Stockscreener App
9.19
0.05%
-0.00
Aurinia Pharmaceuticals Inc stock is traded at $9.19, with a volume of 620.48K.
It is down -0.05% in the last 24 hours and up +14.10% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$9.19
Open:
$9.18
24h Volume:
620.48K
Relative Volume:
0.43
Market Cap:
$1.24B
Revenue:
$175.51M
Net Income/Loss:
$-78.02M
P/E Ratio:
-17.34
EPS:
-0.53
Net Cash Flow:
$-34.18M
1W Performance:
+1.27%
1M Performance:
+14.10%
6M Performance:
+14.81%
1Y Performance:
+65.20%
1-Day Range:
$9.08
$9.36
1-Week Range:
$8.55
$9.36
52-Week Range:
$5.195
$10.67
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
9.19 | 1.20B | 175.51M | -78.02M | -34.18M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.04 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.27 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.48 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
587.90 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.84 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
What analysts say about Aurinia Pharmaceuticals Inc. stockDynamic profit expansion - Autocar Professional
Is Aurinia Pharmaceuticals Inc. a good long term investmentUnmatched profit potential - Autocar Professional
What drives Aurinia Pharmaceuticals Inc. stock priceHigh-yield investments - jammulinksnews.com
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 - BioSpace
Aurinia Pharmaceuticals to Announce Q2 2025 Financial Results - TipRanks
Aurinia Pharmaceuticals: LUPKYNIS Growth and AUR200 Pipeline Fuel Long-Term Value - AInvest
ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting - Yahoo.co
Aurinia Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough investment results - jammulinksnews.com
(AUPH) Technical Data - news.stocktradersdaily.com
Aurinia Pharmaceuticals (NASDAQ:AUPH) Delivers Shareholders Favorable 52% Return Over 1 Year, Surging 5.5% in the Last Week Alone - 富途牛牛
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo
What makes Aurinia Pharmaceuticals Inc. stock price move sharplyDaily Breakout Picks - Newser
How Aurinia Pharmaceuticals Inc. stock performs during market volatilityFree Stock Investment Discussion Area - Newser
Why Aurinia Pharmaceuticals Inc. stock attracts strong analyst attentionReal Trader Insights - Newser
How did AUPH's Q3 2024 earnings surprise impact short-term traders? - AInvest
Trading (AUPH) With Integrated Risk Controls - news.stocktradersdaily.com
Wheat from chaff in BAFF: APRIL’s advent for Aurinia? - BioWorld MedTech
The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity (NASDAQ:AUPH) - Seeking Alpha
Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results - MSN
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options - Nasdaq
Implied Volatility Surging For Aurinia Pharmaceuticals Stock Options - Barchart.com
Leerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH) - The Globe and Mail
Aurinia’s aritinercept shows promising results in phase 1 study - Investing.com
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) - New Castle News
(AUPH) Trading Report - news.stocktradersdaily.com
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? - Yahoo Finance
Aurinia shares rise ahead of key autoimmune therapy data - Proactive financial news
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 50%, as stock drops 5.0% this past week - simplywall.st
With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns - Yahoo Finance
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
California State Teachers Retirement System Sells 13,824 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aurinia Pharmaceuticals Inc Stock (AUPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 04 '25 |
Sale |
7.92 |
57,607 |
456,247 |
509,276 |
| Donley Matthew Maxwell | Chief Operating Officer |
Mar 03 '25 |
Sale |
8.00 |
65,902 |
527,216 |
739,456 |
| Donley Matthew Maxwell | Chief Operating Officer |
Mar 04 '25 |
Sale |
7.92 |
58,991 |
467,209 |
680,465 |
| TANG KEVIN | Director |
Mar 04 '25 |
Buy |
7.96 |
748,038 |
5,953,304 |
10,029,500 |
3.15%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):